Abbott Laboratories fell on its latest earnings report, but I view this as a buying opportunity. Read the latest analysis on ...

Despite facing headwinds, Abbott Laboratories (ABT) reports robust earnings growth and outlines plans for innovation and ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

Abbott shares sank 8% as Q4 revenue of $11.5B missed the $11.8B target, with nutrition sales dropping 8.9% on price ...

The medical device maker announced it anticipates first quarter adjusted profits per share between $1.12 and $1.18, trailing ...

Abbott Laboratories saw its shares down 10% at the end of trading Thursday, Jan. 22, as the market digested weaknesses from its fourth-quarter and full-year earnings report. | Abbott Laboratories saw ...

The mixed earnings report comes on the heels of the Abbott Park, IL-based company announcing it would acquire Exact Sciences for $21 billion.

On Thursday, three companies traded on heavy volume, while their stock prices fell by a meaningful amount. GE Aerospace (GE) ...

Abbott's fourth quarter revenue missed expectations in its devices, diagnostics and nutrition segments, while staying in line for its established pharmaceutical business.

Abbott Laboratories (NYSE: ABT) doesn’t just pay dividends. It grows them. For 52 consecutive years. That’s Dividend King ...

Abbott Laboratories (ABT) stock falls as underperformance in the company's Nutrition segment leads it to record lower than expected Q4 sales. Read more here.